NeOnc Technologies Holdings, Inc.

Healthcare · Biotechnology · United States

Last price 3.26 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 81.03M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary bra...